This product belongs to the macrolide antibiotics, which is the ethyl succinate of erythromycin. It is more stable than erythromycin in gastric acid. This product is an antibacterial agent, but it also has a bactericidal effect on certain bacteria at high concentrations. It has antibacterial activity against Staphylococcus (including enzyme-producing strains), various groups of streptococci and Gram-positive bacilli. Neisseria, Haemophilus influenzae, Bordetella pertussis, etc. are also sensitive to this product. This product also has antibacterial effects on various anaerobic bacteria except Bacteroides fragilis and Fusobacterium. It also has inhibitory effects on Legionella, Campylobacter fetus, certain spirochetes, Mycoplasma pneumoniae, Rickettsia and Chlamydia. This product can penetrate the bacterial cell membrane and reversibly bind to the 50S subunit of the bacterial ribosome near the donor site (P site), blocking the transfer RNA (t-RNA) binding to the P site, and also blocking the displacement of the polypeptide chain from the acceptor site (A site) to the P site, thereby inhibiting bacterial protein synthesis.

Nimodipine is a Ca2 channel blocker that inhibits smooth muscle contraction and relieves vascular spasm by preventing Ca2 from entering cells. It has a strong effect on cerebral arteries, can penetrate the blood-brain barrier, dilate cerebral blood vessels, increase cerebral blood flow, reduce ischemic brain damage, and protect and promote memory and intellectual recovery.

This product is a quinolone antibacterial drug. It has high antibacterial activity against Enterobacteriaceae such as Escherichia coli, Shigella, Klebsiella, Proteus, Enterobacter, etc.; Haemophilus influenzae and Neisseria gonorrhoeae are also highly sensitive to this product; it also has certain antibacterial effects on Pseudomonas such as Acinetobacter, Pseudomonas aeruginosa, Staphylococcus, Pneumococcus, and hemolytic Streptococcus. This product acts on the A subunit of DNA helicase in bacterial cells, inhibiting the synthesis and replication of DNA and exerting a bactericidal effect.

This product is a second-generation sulfonylurea antidiabetic drug, which is effective for most patients with type 2 diabetes. It can reduce fasting and postprandial blood sugar and reduce glycosylated hemoglobin (HbAlc) by 1% to 2%. The main function of this type of drug is to stimulate pancreatic b cells to secrete insulin, but the prerequisite is that pancreatic b cells still have a certain function of synthesizing and secreting insulin. Its mechanism is to specifically bind to the sulfonylurea receptor on the b cell membrane, thereby closing the K channel, causing changes in membrane potential, opening the Ca2 channel, and increasing intracellular Ca2, which promotes insulin secretion. In addition, there are extra-pancreatic effects, including improving the insulin resistance of peripheral tissues (such as liver, muscle, and fat).

This product is a benzimidazole compound. After oral absorption, it is transferred to the gastric mucosa and converted into an active metabolite under acidic conditions. The activated body specifically inhibits the H/K-ATPase system of gastric parietal cells and blocks the final step of gastric acid secretion. This product inhibits basal gastric acid secretion and gastric acid secretion under stimulation in a dose-dependent manner. This product has no antagonistic effect on choline and amine H2 receptors.